ARA 290

DRUG2 trials

Sponsors

Claes-Göran Östenson, Araim Pharmaceuticals, Inc.

Conditions

Diabetes Type 2Impaired Fasting GlucoseImpaired Glucose ToleranceNeuropathy of Sarcoidosis

Phase 2

ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)

Claes-Göran ÖstensonDiabetes Type 2, Impaired Fasting Glucose, Impaired Glucose Tolerance

Start: 2013-10-31End: 2015-12-31Target: 24Updated: 2015-09-03

Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis

CompletedNCT02039687

Araim Pharmaceuticals, Inc.Neuropathy of Sarcoidosis

Start: 2014-01-31End: 2015-02-28Updated: 2017-04-18